Please make sure your browser supports JavaScript and cookies and that you are not blocking them from loading. Mavacamten is being developed to treat obstructive and non-obstructive forms of a condition called hypertrophic cardiomyopathy - estimated to affect one in every 500 people globally. Mavacamten is being developed to treat obstructive and non-obstructive forms of a condition called hypertrophic cardiomyopathy - estimated to affect one in every 500 people globally. For more information you can review our Terms of Service and Cookie Policy. MyoKardia expects to submit marketing application to the U.S. health regulator for obstructive HCM in the first quarter of 2021 after the drug met the main goal of a late-stage study.
Raisingosed-head does not want to personally apply to a study.
( z0 want :ARG0 ( z1 head :ARG1-of ( z2 raise ) ) :ARG1 ( z3 apply :ARG0 z1 :ARG1 ( z4 study ) :ARG1-of ( z5 personal ) ) :polarity - )
(z0 / want-01
    :ARG0 (z1 / head
              :ARG1-of (z2 / raise-01))
    :ARG1 (z3 / apply-01
              :ARG0 z1
              :ARG1 (z4 / study-01)
              :ARG1-of (z5 / personal-02))
    :polarity -)
Raisingosed - head does not want to personally apply to a study .
z1 :ARG1-of z2
z0 :polarity 0
z0 :ARG0 z1
z3 :ARG1-of z5
z0 :ARG1 z3
z3 :ARG0 z1
z3 :ARG1 z4